DK2162143T3 - MAMMALS MILK-MICRO-FORMATIONS incorp-border THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS - Google Patents
MAMMALS MILK-MICRO-FORMATIONS incorp-border THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS Download PDFInfo
- Publication number
- DK2162143T3 DK2162143T3 DK08760355.1T DK08760355T DK2162143T3 DK 2162143 T3 DK2162143 T3 DK 2162143T3 DK 08760355 T DK08760355 T DK 08760355T DK 2162143 T3 DK2162143 T3 DK 2162143T3
- Authority
- DK
- Denmark
- Prior art keywords
- strains
- probiotic
- treatment
- milk
- bacteria
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 41
- 208000004396 mastitis Diseases 0.000 title claims description 38
- 241000124008 Mammalia Species 0.000 title description 8
- 239000006041 probiotic Substances 0.000 claims description 109
- 235000018291 probiotics Nutrition 0.000 claims description 109
- 230000000529 probiotic effect Effects 0.000 claims description 87
- 241000894006 Bacteria Species 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 48
- 241001465754 Metazoa Species 0.000 claims description 33
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 12
- 241000186000 Bifidobacterium Species 0.000 claims description 10
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 10
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 9
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 8
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 210000004877 mucosa Anatomy 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 206010061217 Infestation Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010774 Constipation Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 210000003754 fetus Anatomy 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 235000013336 milk Nutrition 0.000 description 49
- 239000008267 milk Substances 0.000 description 49
- 210000004080 milk Anatomy 0.000 description 49
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 210000005075 mammary gland Anatomy 0.000 description 21
- 230000001580 bacterial effect Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 14
- 239000008272 agar Substances 0.000 description 14
- 241000186660 Lactobacillus Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 13
- 235000014655 lactic acid Nutrition 0.000 description 13
- 239000004310 lactic acid Substances 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 11
- 235000020256 human milk Nutrition 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000004251 human milk Anatomy 0.000 description 10
- 229940039696 lactobacillus Drugs 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000011321 prophylaxis Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241000186012 Bifidobacterium breve Species 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 239000003833 bile salt Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000186840 Lactobacillus fermentum Species 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282465 Canis Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229940093761 bile salts Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940012969 lactobacillus fermentum Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000194033 Enterococcus Species 0.000 description 3
- 241000194032 Enterococcus faecalis Species 0.000 description 3
- 241000282324 Felis Species 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 241000186869 Lactobacillus salivarius Species 0.000 description 3
- 206010039438 Salmonella Infections Diseases 0.000 description 3
- 229940124842 Salmonella vaccine Drugs 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 229940032049 enterococcus faecalis Drugs 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 206010039447 salmonellosis Diseases 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241001019510 Bifidobacterium breve CECT 7263 Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 2
- 241000194029 Enterococcus hirae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004979 bone marrow derived macrophage Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 101150016954 efg1 gene Proteins 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 101150100117 gfm1 gene Proteins 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- YKQOSKADJPQZHB-RGYSVOEGSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(6r,9s,12r,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydr Chemical compound CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)C([C@@H](C)O)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-RGYSVOEGSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 208000030770 patent ductus arteriosus 3 Diseases 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 101000746317 Bos taurus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 206010006261 Breast infections Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 101150088517 TCTA gene Proteins 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000004883 areola Anatomy 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 108010006741 lactobacterin Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 108010049023 pediocin PA-1 Proteins 0.000 description 1
- ZRUMXHGBGLWVDT-SJMRFLIKSA-N pediocin pa 1 Chemical compound C([C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@H](CC=2NC=NC=2)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(O)=O)C1=CN=CN1 ZRUMXHGBGLWVDT-SJMRFLIKSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000007692 rcm medium Substances 0.000 description 1
- 230000002629 repopulating effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
- A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07380158A EP1997499A1 (en) | 2007-05-31 | 2007-05-31 | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis |
| PCT/EP2008/056768 WO2008145756A1 (en) | 2007-05-31 | 2008-06-02 | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2162143T3 true DK2162143T3 (en) | 2015-12-14 |
Family
ID=38657070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08760355.1T DK2162143T3 (en) | 2007-05-31 | 2008-06-02 | MAMMALS MILK-MICRO-FORMATIONS incorp-border THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8557560B2 (enExample) |
| EP (2) | EP1997499A1 (enExample) |
| JP (1) | JP5710250B2 (enExample) |
| AU (1) | AU2008257455B2 (enExample) |
| CA (1) | CA2689360C (enExample) |
| CO (1) | CO6270334A2 (enExample) |
| DK (1) | DK2162143T3 (enExample) |
| ES (1) | ES2555159T3 (enExample) |
| HU (1) | HUE025851T2 (enExample) |
| IL (1) | IL202386A0 (enExample) |
| MX (1) | MX2009013044A (enExample) |
| NZ (1) | NZ581576A (enExample) |
| PL (1) | PL2162143T3 (enExample) |
| PT (1) | PT2162143E (enExample) |
| RU (1) | RU2446814C2 (enExample) |
| WO (1) | WO2008145756A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010103132A1 (es) * | 2009-03-10 | 2010-09-16 | Hero España, S.A. | Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| RU2476591C1 (ru) * | 2011-08-19 | 2013-02-27 | Федеральное государственное образовательное учреждение высшего профессионального образования "Горский государственный аграрный университет" | Штамм enterococcus hirae, используемый для приготовления кисломолочных продуктов |
| RU2477313C1 (ru) * | 2011-08-25 | 2013-03-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Горский государственный аграрный университет" | ШТАММ Enterococcus hirae, ИСПОЛЬЗУЕМЫЙ ПРИ ПРОИЗВОДСТВЕ КИСЛОМОЛОЧНЫХ ПРОДУКТОВ |
| RU2476592C1 (ru) * | 2011-09-02 | 2013-02-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Горский государственный аграрный университет" | Штамм enterococcus hirae, используемый для производства кисломолочных продуктов |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN109172816A (zh) | 2012-03-29 | 2019-01-11 | 塞拉拜姆有限责任公司 | 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂 |
| RU2015140610A (ru) | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| AU2014256851B2 (en) | 2013-04-23 | 2019-04-18 | Terragen Holdings Limited | Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same |
| DE102013105666A1 (de) * | 2013-06-03 | 2014-12-04 | Hochschule Hannover | Probiotische Stämme, Zusammensetzungen enthaltend probiotische Stämme sowie pharmazeutische Mittel |
| EP2818056A1 (en) | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
| US9805171B2 (en) | 2013-08-23 | 2017-10-31 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
| US9811641B2 (en) | 2013-08-23 | 2017-11-07 | Elwha Llc | Modifying a cosmetic product based on a microbe profile |
| US10010704B2 (en) | 2013-08-23 | 2018-07-03 | Elwha Llc | Systems, methods, and devices for delivering treatment to a skin surface |
| US20150057574A1 (en) | 2013-08-23 | 2015-02-26 | Elwha Llc | Selecting and Delivering Treatment Agents based on a Microbe Profile |
| US9390312B2 (en) | 2013-08-23 | 2016-07-12 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
| US9456777B2 (en) | 2013-08-23 | 2016-10-04 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
| US9557331B2 (en) | 2013-08-23 | 2017-01-31 | Elwha Llc | Systems, methods, and devices for assessing microbiota of skin |
| US10152529B2 (en) | 2013-08-23 | 2018-12-11 | Elwha Llc | Systems and methods for generating a treatment map |
| EP2862576B1 (en) | 2013-10-16 | 2016-12-14 | Casen Recordati, S.L. | Microorganisms and compositions comprising them for use in the treatment or prevention of mastitis |
| WO2015093937A1 (en) * | 2013-12-19 | 2015-06-25 | N.V. Nutricia | Lactobacillus salivarius for the treatment of mastitis |
| KR102517581B1 (ko) * | 2014-10-21 | 2023-04-03 | 아퀼론 씨와이엘 에스.엘. | 프로바이오틱 및 프리바이오틱 조성물 |
| PT3065748T (pt) | 2014-12-23 | 2018-02-28 | 4D Pharma Res Ltd | Uma estirpe de bacteroides thetaiotaomicron e o seu uso na redução da inflamação |
| BR112017013274A2 (pt) | 2014-12-23 | 2018-02-06 | 4D Pharma Research Limited | polipeptídeo e imunomodulação |
| HK1248756A1 (zh) * | 2015-01-16 | 2018-10-19 | Biogaia Ab | 乳酸菌及其用於治疗乳腺炎的用途 |
| WO2016120405A1 (en) * | 2015-01-30 | 2016-08-04 | Technische Universität München | Composition for use in preventing and/or treating diarrhea in animals |
| WO2016161074A1 (en) | 2015-03-31 | 2016-10-06 | Gojo Industries, Inc. | Synergistic compositions and methods for mitigating skin irritation and enhancing skin barrier function |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PL3307288T3 (pl) | 2015-06-15 | 2019-12-31 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| PT3360559T (pt) | 2015-06-15 | 2020-01-06 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| SK542015A3 (sk) * | 2015-07-30 | 2017-02-02 | Univerzita Pavla Jozefa Šafárika V Košiciach | Kmene mikroorganizmov Lactobacillus Plantarum LS/07 CCM 7766 a spôsob ich využitia |
| HUE036362T2 (hu) | 2015-11-20 | 2018-07-30 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US11071760B2 (en) * | 2015-12-24 | 2021-07-27 | Dairy A Day Inc. | Compositions and methods of use of novel strains of Lactobacillus fermentum |
| PL3313423T3 (pl) | 2016-03-04 | 2019-09-30 | 4D Pharma Plc | Kompozycje zawierające szczepy bakteryjne blautia do leczenia nadwrażliwości trzewnej |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MY199866A (en) * | 2017-01-13 | 2023-11-26 | Bened Biomedical Co Ltd | A novel lactic acid bacteria and its applications |
| JP7212945B2 (ja) | 2017-05-22 | 2023-01-26 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| AU2018285445B2 (en) | 2017-06-14 | 2020-03-26 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
| PT3638271T (pt) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Ltd | Composições contendo estirpes bacterianas |
| HUE059249T2 (hu) | 2017-06-14 | 2022-11-28 | 4D Pharma Res Limited | Baktériumtörzseket tartalmazó készítmények |
| EP3769772A4 (en) | 2018-03-23 | 2021-11-24 | Morinaga Milk Industry Co., Ltd. | COMPONENT FOR IMPROVING A BREAST MILK COMPONENT |
| WO2020194298A1 (en) * | 2019-03-25 | 2020-10-01 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Method of treating bovine mastitis |
| US20220288135A1 (en) * | 2019-07-08 | 2022-09-15 | BioPlx, Inc. | Live biotherapeutic compositions and methods |
| EP4065146A1 (en) * | 2019-11-29 | 2022-10-05 | Société des Produits Nestlé S.A. | Compositions and methods with a probiotic and a nutrient and/or mineral for the prevention or treatment of mastitis |
| CL2019003739A1 (es) * | 2019-12-18 | 2020-06-19 | Univ Concepcion | Cepas probióticas de lactobacillus sp. y de pediococcus sp. y su uso en la elaboración de una formulación probiótica para prevención de diarreas causadas por patógenos bacterianos que afectan a perros y gatos. |
| JP2022150100A (ja) * | 2021-03-26 | 2022-10-07 | 清竺 遠藤 | 乳汁の体細胞数減少用又は乳量増加用組成物 |
| CN117338823A (zh) * | 2023-12-06 | 2024-01-05 | 山东百德生物科技有限公司 | 一种动物酵素发酵液及其制备方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4591499A (en) | 1984-01-20 | 1986-05-27 | J. B. Lima, Inc. | Method for treatment and prevention of mastitis |
| ATE172245T1 (de) * | 1992-07-06 | 1998-10-15 | Nestle Sa | Milchbakterien |
| US5837238A (en) * | 1996-06-05 | 1998-11-17 | Biogaia Biologics Ab | Treatment of diarrhea |
| DK1565547T4 (da) * | 2002-06-28 | 2013-01-14 | Biosearch S A | Probiotiske stammer, en fremgangsmåde til selektion deraf, præparater deraf samt anvendelse deraf |
| IE20030773A1 (en) * | 2003-10-17 | 2005-04-20 | Teagasc Agric Food Dev Authori | Use of probiotic bacteria in the treatment of infection |
| WO2005085287A1 (en) * | 2004-03-03 | 2005-09-15 | En-N-Tech, Inc. | Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions |
| US7955834B2 (en) * | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
-
2007
- 2007-05-31 EP EP07380158A patent/EP1997499A1/en not_active Withdrawn
-
2008
- 2008-06-02 MX MX2009013044A patent/MX2009013044A/es active IP Right Grant
- 2008-06-02 NZ NZ581576A patent/NZ581576A/en unknown
- 2008-06-02 EP EP08760355.1A patent/EP2162143B1/en active Active
- 2008-06-02 HU HUE08760355A patent/HUE025851T2/en unknown
- 2008-06-02 AU AU2008257455A patent/AU2008257455B2/en active Active
- 2008-06-02 PL PL08760355T patent/PL2162143T3/pl unknown
- 2008-06-02 RU RU2009149393/15A patent/RU2446814C2/ru active
- 2008-06-02 ES ES08760355.1T patent/ES2555159T3/es active Active
- 2008-06-02 JP JP2010509847A patent/JP5710250B2/ja active Active
- 2008-06-02 DK DK08760355.1T patent/DK2162143T3/en active
- 2008-06-02 PT PT87603551T patent/PT2162143E/pt unknown
- 2008-06-02 WO PCT/EP2008/056768 patent/WO2008145756A1/en not_active Ceased
- 2008-06-02 CA CA2689360A patent/CA2689360C/en active Active
- 2008-06-02 US US12/602,182 patent/US8557560B2/en active Active
-
2009
- 2009-11-26 IL IL202386A patent/IL202386A0/en unknown
- 2009-12-30 CO CO09149368A patent/CO6270334A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2009149393A (ru) | 2011-07-10 |
| RU2446814C2 (ru) | 2012-04-10 |
| EP2162143A1 (en) | 2010-03-17 |
| US20100266550A1 (en) | 2010-10-21 |
| AU2008257455B2 (en) | 2014-05-01 |
| CA2689360C (en) | 2017-03-14 |
| CA2689360A1 (en) | 2008-12-04 |
| NZ581576A (en) | 2012-01-12 |
| EP1997499A1 (en) | 2008-12-03 |
| AU2008257455A1 (en) | 2008-12-04 |
| IL202386A0 (en) | 2010-06-30 |
| HUE025851T2 (en) | 2016-04-28 |
| JP5710250B2 (ja) | 2015-04-30 |
| JP2010528093A (ja) | 2010-08-19 |
| US8557560B2 (en) | 2013-10-15 |
| ES2555159T3 (es) | 2015-12-29 |
| PL2162143T3 (pl) | 2016-03-31 |
| WO2008145756A1 (en) | 2008-12-04 |
| PT2162143E (pt) | 2016-01-07 |
| EP2162143B1 (en) | 2015-09-09 |
| BRPI0811973A2 (pt) | 2014-10-21 |
| MX2009013044A (es) | 2010-04-12 |
| CO6270334A2 (es) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2162143T3 (en) | MAMMALS MILK-MICRO-FORMATIONS incorp-border THEM AND THEIR USE FOR THE TREATMENT OF MASTITIS | |
| US11759486B2 (en) | Lactobacillus plantarum and composition comprising same | |
| JP4176715B2 (ja) | プロバイオティクス菌株、その選択方法、その組成物、およびその使用 | |
| DK2494031T3 (en) | Novel lactobacillus plantarum and composition comprising the same | |
| TW202237814A (zh) | 戴白氏乳桿菌乳酸亞種ldl557分離株及其用途 | |
| EP2220210B1 (en) | Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect | |
| EP1997880A1 (en) | Breast milk bifidobacteria, compositions thereof, their use and a novel culture media to obtain them | |
| RU2708146C2 (ru) | Средство для улучшения состояния пищеварения | |
| BRPI0811973B1 (pt) | Processo para a seleção de probióticos, cepa probiótica, sobrenadante, composição, produto farmacêutico, alimento ou produto nutricional e uso de uma cepa probiótica |